‍Separating Fact from Fiction About GLP-1s and Muscle Loss

As GLP-1 medications continue to gain attention, one concern frequently emerges: muscle loss.

Current evidence suggests this topic requires context, because weight loss from many interventions like caloric restriction, bariatric surgery and others may also involve lean muscle mass changes ⁽¹⁾. The amount can vary by individual and may be influenced by nutrition, exercise, and clinical support among others.

Skeletal muscle health is determined not only by muscle quantity (the size and number of muscle cells) but also by muscle quality, which is determined by factors such as strength, composition, insulin sensitivity, and physical function.

As we are beginning to understand this distinction, it is hypothesized that GLP-1 agonists may help preserve muscle quality through improvements in insulin sensitivity and metabolic health, potentially reducing the risk of decline in strength and physical function, despite the changes in the lean muscle mass ^{[C1] (2)}.

‍

‍

Preserving Lean Mass During Weight Loss

Nonetheless, lean muscle mass can be preserved by adapting a proactive and strategic approach to weight loss..

As patients lose weight, increasing physical activity becomes increasingly significant. Resistance training helps support muscle maintenance, while aerobic exercise supports cardiovascular health and overall fitness.

Nutrition also plays a role. Adequate protein intake, individualized nutrition strategies, and ongoing clinical support may help individuals maintain lean mass throughout their weight loss journey.

Several obesity and nutrition organizations now recommend higher protein intake than the standard Recommended Dietary Allowance, typically 1.2–1.6 g of protein per kg of body weight (or ideal body weight) per day, combined with resistance training.

Practical Daily Targets

Furthermore, protein consumption should ideally be spread throughout the day, aiming for 25–40 grams per meal rather than consuming most of it at dinner⁽³⁾.

It is crucial to keep in mind that protein alone is insufficient. Structured resistance or strength training is key to preserve lean mass as excess dietary protein without exercise stimulus can be converted to fat.

‍

The Next Evolution of Obesity Care

The growing conversation around muscle preservation is an essential shift that is helping shape the next phase of obesity treatment.

Researchers and healthcare organizations are exploring new therapies designed to complement weight management strategies. Some investigational peptide-based therapies are being studied for potential effects on body composition, but clinical evidence, regulatory status, and appropriate use vary.

‍

Evaluating the Emerging Peptide Landscape

The peptide market has expanded rapidly in recent years, often outpacing the clinical data available to support many of these products. Hence, we need to approach them with a strong emphasis on clinical evidence and safety.

There are a few peptide-based human clinical trials that show increased muscle hypertrophy, meaning larger muscles, but in real life, the individuals in the trials had no improved physical fitness. This further reinforces the important difference between the muscle quantity and quality discussed above.

‍

‍

Why Evidence Matters and Looking Ahead

At eMed, our approach remains grounded in interventions supported by clinical evidence.

Today, that means prioritizing strategies intended to help preserve lean mass while supporting weight loss, including:

• Resistance training
• Nutrition optimization
• Behavioral support
• Clinically supervised GLP-1 therapy

As new therapies emerge, they should be evaluated through the same evidence-based lens.

The peptide space is evolving from a fragmented, unregulated market to a more evidence-based, FDA-governed category, similar to what we've seen with GLP-1s. The future belongs to therapies with strong clinical data, consistent manufacturing, and scalable care models.

While weight loss remains an important outcome, healthcare providers are increasingly evaluating additional critical factors that may contribute to overall health.

‍

_{Disclaimer: This blog is maintained by eMed for informational purposes only. Content published here does not constitute medical, legal, financial, or benefits advice and should not be relied upon as such. Third-party statistics, studies, and research cited are sourced from publicly available data and provided for general informational context only; eMed makes no representation as to their accuracy, completeness, or applicability to any specific employer population, and results may vary. eMed's GLP-1 program pairs FDA-approved, on-label medications with clinical oversight; individual health outcomes depend on a variety of clinical and personal factors and cannot be guaranteed. References in this article to investigational, compounded, or non-FDA-approved therapies, including peptides, are provided solely for educational discussion and do not constitute promotion, endorsement, a recommendation, or an offer of any such product. eMed’s GLP-1 program is limited to FDA-approved medications used on-label and does not include investigational or non-FDA-approved therapies. Any nutrition, protein, or exercise figures are general educational ranges, not individualized medical or dietary advice; consult a qualified healthcare provider before making any changes.}

_{Any content contributed by eMed's Chief Medical Officer is provided in her personal capacity as a licensed physician for general informational purposes only. Such content does not constitute medical advice from eMed, establish a physician-patient relationship, or represent eMed's official clinical guidance. Readers should not act on any health-related information without first consulting a qualified healthcare provider.}

_{Employers and individuals should consult qualified legal, benefits, and medical advisors before making plan design, coverage, or healthcare decisions. eMed assumes no liability for decisions made based on information contained in this blog.}

References

1. Mocciaro G, Capodici A, De Amicis R. GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction. BMJ Nutr Prev Health. 2025;8(1):e001206.
2.  Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(1):16-27.
3. 2025 Joint Advisory — ACLM, ASN, OMA, The Obesity Society

‍